Intellia Therapeutics旗下Haleo研究达到主要终点,Lonvo-Z组平均月发作次数降低87% (P<0.0001)

美股速递
Jun 13

Intellia Therapeutics宣布,其Haleo研究成功达到主要终点。数据显示,在Lonvo-Z治疗组中,患者平均每月发作次数实现了高达87%的显著降低,且该结果具有高度统计学意义(P值小于0.0001)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10